Good news for IOL Chemicals and Pharmaceuticals Ltd! The Indian pharmaceutical and chemicals manufacturer has successfully finished an inspection by the Brazilian Health Regulatory Agency (ANVISA). This successful audit of their 10 Active Pharmaceutical Ingredient (API) manufacturing units in Barnala, Punjab, indicates a major milestone for IOL Chemicals, as it is opening doors to the lucrative Brazilian market.
After the news came in, the share price of IOL Chemicals witnessed a positive impact from investors, which opened at ₹369 and touched the day high of ₹412.30 on March 19, 2024, at 12:50 PM.
ANVISA, the Brazilian equivalent of India’s CDSCO (Central Drugs Standard Control Organization), plays a vital role in ensuring the quality, safety, and efficacy of drugs sold in Brazil. The ANVISA Good Manufacturing Practice (GMP) audit rigorously evaluates a pharmaceutical company’s manufacturing facilities, processes, and quality control measures. A successful audit like the one achieved by IOL Chemicals demonstrates its adherence to international quality standards.
Brazil is one of the leading pharmaceutical markets, presenting a significant growth opportunity for IOL Chemicals. Here’s how the successful ANVISA audit benefits them:
The successful completion of the ANVISA GMP audit marks a significant achievement for IOL Chemicals. It unlocks access to the lucrative Brazilian market, enhances their reputation, and strengthens their competitive position.
IOL Chemicals & Pharmaceuticals Ltd is one of the leading pharmaceutical (APIs) companies and is a significant player in the speciality chemicals space. The company caters to the domestic and export markets.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Mar 19, 2024, 2:28 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates